AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection

AstraZeneca Plc AZN has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.
The application seeks approval for AZD7442 to prevent COVID-19 for people who respond poorly to vaccines because of a weakened immune system.
Related: AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%.
If approved, AZD7442 would be the first LAAB to receive a EUA for COVID-19 prevention.
Talks regarding supply agreements for AZD7442 are ongoing with the United States and other governments.
AZD7442 was optimized using AstraZeneca's proprietary YTE half-life extension technology, which more than triples the durability of its action compared to conventional antibodies.
Preliminary 'in vitro' findings of AZD7442 demonstrated broad anti-COVID activity, particularly neutralized viral variants, including the Delta and Mu variants.
Related Link: Merck COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%.
Price Action: AZN stock is down 0.31% at $60.35 during the premarket session on the last check Tuesday.